Article
Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity.
Brain : a journal of neurology - 3 Jun 2022
Ruck Tobias, Barman Sumanta, Schulte-Mecklenbeck Andreas, Pfeuffer Steffen, Steffen Falk, Nelke Christopher, Schroeter Christina B, Willison Alice, Heming Michael, Müntefering Thomas, Melzer Nico, Krämer Julia, Lindner Maren, Riepenhausen Marianne, Gross Catharina C, Klotz Luisa, Bittner Stefan, Muraro Paolo A, Schneider-Hohendorf Tilman, Schwab Nicholas, Meyer Zu Hörste Gerd, Goebels Norbert, Meuth Sven G, Wiendl Heinz
Abstract excerpt
Alemtuzumab is a monoclonal antibody that causes rapid depletion of CD52-expressing immune cells. It has proven to be highly efficacious in active relapsing-remitting multiple sclerosis; however, the high risk of secondary autoimmune disorders has greatly complicated its use. Thus, deeper insight into the pathophysiology of secondary autoimmunity and potential biomarkers is urgently needed. The most critical time...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.